Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Laurie H Sehn, MD, David W. Scott, MBChB, PhD, Diego Villa, MD FRCPC, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Pedro Farinha, MD PhD, Graham W Slack, MD PhD, Don Wilson, MD, R. Petter Tonseth, MD, Joseph M. Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 401.

https://doi.org/10.1182/blood-2019-128722

Published: 2019

Journal Articles

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1478.

https://doi.org/10.1182/blood-2019-129136

Published: 2019

Journal Articles

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Phoebe Tsz Man Cheng, BSc,MD, Diego Villa, MD MPH, R. Petter Tonseth, MD, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Don Wilson, MD, Brian Skinnider, MD, Laurie H Sehn, MD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 2845.

https://doi.org/10.1182/blood-2019-122019

Published: 2019

Journal Articles

Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

Diego Villa, MD MPH, Laurie H Sehn, MD, Kerry J Savage, BSc, MD MSc, Cynthia L Toze, MD FRCPC, Kevin Song, MD, Wendie L den Brok, Ciara L Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 2814.

https://doi.org/10.1182/blood-2019-124217

Published: 2019

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Elysha Vanderveer, MD BSc, Steven J.T. Huang, BMLSc, Helene Bruyere, MD FCCMG, Tanya Gillan, PhD FCCMG, Charles H. Li, MDFRCPC, Khaled Ramadan, MBBCH, MRCP, FRCPath, Diego Villa, MD MPH, David W. Scott, MBChB, PhD, Kerry J Savage, BSc, MD MSc, Joseph M Connors, MD, Laurie H Sehn, MD, Cynthia L Toze, MD FRCPC, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 4300.

https://doi.org/10.1182/blood-2019-125189

Published: 2019

Journal Articles

Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma

Robert Kridel, MDMPH,PhD, Keren Isaev, MSc, Daisuke Ennishi, MD PhD, Brian Skinnider, MD, Karen Mungall, PhD, Andrew J. Mungall, PhD, Mehran Bakhtiari, MSc, Rosemarie Tremblay-Lemay, MD MSc, FRCPC, Barbara Meissner, PhD, Susana Ben-Neriah, BSc, Merrill Boyle, BSc, Diego Villa, MD MPH, Marco A. Marra, PhD, Christian Steidl, MD, Randy D. Gascoyne, MD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 2763.

https://doi.org/10.1182/blood-2019-124235

Published: 2019

Journal Articles

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Clare Gould, MBBS, Jennifer Lickiss, MSc, BSc, Yamuna Kankanige, Satwica Yerneni, MS, John Markham, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Diego Villa, MD MPH, Graham W Slack, MD, Collin Chin, MBBS, Constantine S. Tam, MBBS (Hons), MD, Stephen Lade, MBBS, FRCPA, Niles Elizabeth Nelson, BSc, MBBS, Paul J Neeson, BSc, PhD, John F. Seymour, MBBS, PhD FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 4290.

https://doi.org/10.1182/blood-2019-127800

Published: 2019

Journal Articles

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Diego Villa, MD, Graham W Slack, MD PhD, Muntadhar Al-Moosawi, MD, Susana Ben-Neriah, BSc, Tamara Shenkier, MD, Joseph M. Connors, MD, Laurie H Sehn, MDMPH, Kerry J Savage, BSc, MD MSc, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD, Randy D. Gascoyne, MD, King Tan, MD

Blood (2018) 132 (Supplement 1): 348.

https://doi.org/10.1182/blood-2018-99-114218

Published: 2018

Journal Articles

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

Blood (2018) 132 (Supplement 1): 921.

https://doi.org/10.1182/blood-2018-99-116827

Published: 2018

Journal Articles

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Hatem Alahwal, MPH, MBBS, Parv Chapani, Diego Villa, MD FRCPC, Yasser Abou Mourad, MD, Maryse Power, MD, Stephen H. Nantel, MD, David Sanford, MD, Gayatri Sreenivasan, BSc, MD, Heather J. Sutherland, MD PhD, Laurie H Sehn, MD MPH, Cynthia L. Toze, MD FRCPC, MSc, Raewyn Broady, MBChB, Kevin Song, MD, Paul Yenson, MD BSc, FRCPC, Alina S. Gerrie, MD MPH

Blood (2018) 132 (Supplement 1): 4556.

https://doi.org/10.1182/blood-2018-99-114371

Published: 2018

Journal Articles

Outcomes of Stage I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance

Blood (2018) 132 (Supplement 1): 4148.

https://doi.org/10.1182/blood-2018-99-114097

Published: 2018

Journal Articles

UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation through a Cyclin D1-Dependent Mechanism

Olga Kutovaya, PhD, Stacy Hung, Elena Viganò, PhD, Adele Telenius, Bruce W Woolcock, Barbara Meissner, PhD, Shane Colborne, BSc, Randy D. Gascoyne, MD, Diego Villa, MD, Ryan D. Morin, PhD, BSc, MSc, David W. Scott, PhD MD, FRACP, FRCPA, Gregg B Morin, PhD, Christian Steidl, MD

Blood (2018) 132 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2018-99-118524

Published: 2018

Journal Articles

Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Jorne Lionel Biccler, MSc, BSc, Kerry J Savage, BSc, MD MSc, Peter de Nully Brown, MD PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Christian Bjørn Poulsen, MD, Danny Stoltenberg, MD, Lasse H. Jakobsen, Martin Bøgsted, Professor, Diego Villa, MD, Tarec C. El-Galaly

Blood (2018) 132 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2018-99-114191

Published: 2018

Journal Articles

Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced Stage Hodgkin Lymphoma

Anna R Hayden, MD, Derrick G Lee, PhD, Diego Villa, MD, Alina S. Gerrie, MD MPH, David W. Scott, PhDMD, FRACP, FRCPA, Graham W Slack, MD, Laurie H Sehn, MD MPH, Joseph M. Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2018) 132 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2018-99-111047

Published: 2018

Journal Articles

Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma

Ciara Louise Freeman, MRCP, MSc, FRCPath, MBBChir, Kerry J Savage, BSc, MD MSc, Diego Villa, MD, David W. Scott, PhDMD, FRACP, FRCPA, Alina S. Gerrie, MD MPH, David J Ferguson, Fergus Cafferty, Graham W Slack, MD, Pedro Farinha, MD PhD, Brian Skinnider, Joseph M. Connors, MD, Laurie H Sehn, MD MPH

Blood (2018) 132 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2018-99-113675

Published: 2018

Journal Articles

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Ahmed Sawas, MD, John Kuruvilla, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Francesca Montanari, MD, Kerry J Savage, BSc, MD MSc, Hager Elgedawe, Diego Villa, MD, Michael Crump, MD, Joseph M Connors, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2018-99-117251

Published: 2018

Journal Articles

Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP ± Radiotherapy: An International Multi-Center Retrospective Study

Allison Barraclough, MBBS, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris Van Vliet, Laurie H. Sehn, MDMPH, Vishakha Sovani, Mitchell Steven Ward, Bradley Augustson, Pedro Farinha, Jorne Lionel Biccler, MSc, Joseph M Connors, MD, David W. Scott, MD PhD FRACP, FRCPA, Kerry J Savage, MD, Tarec Christoffer El-Galaly, MD PhD, Diego Villa, MD, Chan Yoon Cheah

Blood (2017) 130 (Supplement 1): 415.

https://doi.org/10.1182/blood.V130.Suppl_1.415.415

Published: 2017

Journal Articles

Long-Term Results of PET-Guided Radiation Therapy in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma Treated with R-CHOP in British Columbia

Ciara Louise Freeman, MRCP, MD, Kerry J Savage, BSc, MD MSc, Diego Villa, MD, David W. Scott, MD PhD FRACP, FRCPA, Line Srour, MD, Alina S Gerrie, MD, Maura J Brown, Graham W Slack, MD, Pedro Farinha, Brian Skinnider, Christina Aquino Parsons, Tom Pickles, MD FRCPC, Pete Tonseth, Don Wilson, Joseph M Connors, MD, Laurie H. Sehn, MDMPH

Blood (2017) 130 (Supplement 1): 823.

https://doi.org/10.1182/blood.V130.Suppl_1.823.823

Published: 2017

Journal Articles

Deciphering Discordance between MYC mRNA and MYC IHC in DLBCL: The Role of MYC Exon 2 Mutations and N11S Polymorphism

Blood (2017) 130 (Supplement 1): 3994.

https://doi.org/10.1182/blood.V130.Suppl_1.3994.3994

Published: 2017

NARROW

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Outcomes of Stage I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance

UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation through a Cyclin D1-Dependent Mechanism

Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma

Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced Stage Hodgkin Lymphoma

Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP ± Radiotherapy: An International Multi-Center Retrospective Study

Long-Term Results of PET-Guided Radiation Therapy in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma Treated with R-CHOP in British Columbia

Deciphering Discordance between MYC mRNA and MYC IHC in DLBCL: The Role of MYC Exon 2 Mutations and N11S Polymorphism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only